Drugs / AZD2820
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01332214 | May → Nov 2011 | — | AstraZeneca | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01469923 Comparator | Mar → Dec 2012 | obesity disorder | AstraZeneca | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2012-09-07 | Palatin Technologies, Inc | Results Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca palatin.com ↗ |
| 2012-06-19 | Palatin Technologies, Inc | Results Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration palatin.com ↗
The Phase 1 clinical trial of AZD2820 was halted by the Safety Review Committee established by AstraZeneca after meeting a predefined stopping criterion. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2012-09-07 | Palatin Technologies, Inc | Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca palatin.com ↗ |
| 2012-06-19 | Palatin Technologies, Inc | Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration palatin.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD2820 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01332214 ↗ |
| Route | Subcutaneous | “Subcutaneous Injection in abdomen or Thigh” NCT01332214 ↗ |